ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LBRX vs SLN // PIOTROSKI F-SCORE QUALITY

LB Pharmaceuticals Inc (NASDAQ) VS. Silence Therapeutics Plc American Depository Share (NASDAQ) • 15-METRIC TALLY: LBRX 3 — SLN 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: SLN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LBRX VS. SLN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LBRX SLN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 61.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -8.40% -35.00% +26.60 LBRX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.72% -5.06% +2.34 LBRX /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.36 — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 3/9 -1.00 SLN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.7 79.0 -24.30 SLN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.30B $1.23B $64.6M LBRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LBRX REV SLN REV LBRX GROSS % SLN GROSS % LBRX FCF SLN FCF
FY 2025 $0 $559.0K — 61.5% -$35.3M -$62.3M
FY 2024 $0 $43.3M — 72.7% -$53.8M -$67.9M
FY 2023 — $31.6M — — — -$49.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LBRX // BETA —
SLN // BETA —